A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

This study is for women who have gone through menopause and have been diagnosed with a specific type of breast cancer: one that is hormone receptor-positive and HER2-negative. The cancer should either have returned in the local area or be metastatic (spread to other parts of the body). You would typically need to be in reasonably good health otherwise, able to swallow capsules, and not have certain other serious health issues like inflammatory breast cancer or cancer in the brain.

There are also some reasons why you might not be able to join. For example, if you've recently had certain other breast cancer treatments, especially other drugs that work in a similar way to abemaciclib, or if your cancer is causing very severe symptoms like a 'visceral crisis' (affecting organs badly). You also can't be taking other experimental drugs or have recently received certain bone-strengthening medications.

If you take part in this study, you'll be randomly assigned to one of two groups: either you'll receive the study drug abemaciclib along with standard hormone therapy, or you'll get a dummy pill (placebo) along with standard hormone therapy. You won't know which group you are in, and neither will the study doctors.

You'll be asked to attend regular clinic visits for examinations, blood tests, and to assess how you're feeling and how the treatment is working. You'll take the study medication as capsules. The total duration of your participation could vary, as you'd continue treatment as long as it's helping and you're not having severe side effects. There would also be follow-up appointments to monitor your health after you stop taking the study medication.